04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival
30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19
16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020
30/09/2020 – AB Science reports its revenues for the first half of 2020
14/09/2020 – AB Science presents Phase 2B/3 study results in Progressive Multiple Sclerosis at the world’s largest Multiple Sclerosis research conference
08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting